Currently, Verona Pharma Plc ADR [VRNA] is trading at $54.17, down -0.24%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The VRNA shares have lost -7.46% over the last week, with a monthly amount drifted -11.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on January 10, 2025, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $68. Previously, Wells Fargo started tracking the stock with Overweight rating on October 03, 2024, and set its price target to $50. Piper Sandler initiated its recommendation with a Overweight and recommended $31 as its price target on August 26, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on September 13, 2021, and assigned it a price target of $25. In a note dated August 25, 2020, Jefferies initiated an Buy rating and provided a target price of $17 on this stock.
This stock has fluctuated between a low of $11.39 and a high of $70.40 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $77.33 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $54.17 at the most recent close of the market. An investor can expect a potential return of 42.75% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -3.66%, Pretax Profit Margin comes in at -3.89%, and Net Profit Margin reading is -4.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.95 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.73 points at the first support level, and at 49.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.02, and for the 2nd resistance point, it is at 59.88.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Verona Pharma Plc ADR [NASDAQ:VRNA] is 10.63. Also, the Quick Ratio is 10.48, while the Cash Ratio stands at 9.37. Considering the valuation of this stock, the price to sales ratio is 109.15, the price to book ratio is 22.41.
Transactions by insiders
Recent insider trading involved Rickard Kathleen A., Chief Medical Officer, that happened on Mar 12 ’25 when 79264.0 shares were sold. Officer, KATHLEEN RICKARD completed a deal on Mar 12 ’25 to buy 9908.0 shares. Meanwhile, President and CEO ZACCARDELLI DAVID sold 0.64 million shares on Dec 05 ’24.
